Strata Critical Medical (SRTA) Liabilities and Shareholders Equity (2019 - 2026)

Strata Critical Medical (SRTA) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $327.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 30.76% year-over-year to $327.6 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 16.4% YoY), while the FY2025 annual figure was $325.5 million, up 26.8% from the prior year.
• Liabilities and Shareholders Equity grew to $327.6 million in Q1 2026 per SRTA's latest filing, from $325.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $335.1 million in Q3 2025 and bottomed at $250.6 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $303.3 million across 5 years, with a median of $320.2 million in 2023.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity decreased 12.97% — and 2026, when it jumped 30.76%.
• Strata Critical Medical's Liabilities and Shareholders Equity stood at $325.0 million in 2022, then declined by 9.26% to $294.9 million in 2023, then fell by 12.97% to $256.7 million in 2024, then gained by 26.8% to $325.5 million in 2025, then gained by 0.66% to $327.6 million in 2026.
• Business Quant data shows SRTA's Liabilities and Shareholders Equity at $327.6 million in Q1 2026, $325.5 million in Q4 2025, and $335.1 million in Q3 2025.